Zimmer Biomet Rolls Out Comprehensive Episode-Of-Care Program

The orthopedics giant is integrating a suite of products and services to help hospitals transition to value-based health-care payment models. The initial focus will be joint-replacement procedures, but Zimmer Biomet anticipates expanding the concept to spine surgery and other sectors.

Zimmer Biomet Holdings Inc. is rolling out the Signature Solutions program, a package of software and consulting services to help hospitals take advantage of the orthopedic surgery industry's ongoing transition from fee-for-service to value-based payment models.

"This is really critical at this time, because more payers are looking at episode-of-care management … and other bundled payment programs," Zimmer Biomet's Joe Tamaro told Medtech Insight. Tamaro is the General Manager of Accelero Health Partners, a subsidiary of Zimmer Biomet that operates the firm's consulting division

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

More from Medtech Insight

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.